| AGLE Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the AGLE shares outstanding history going back to 4/7/2016:
Also see: AGLE Market Cap History AGLE YTD Return |
AGLE Shares Outstanding History — Aeglea BioTherapeutics Share Count Over Time
As of 11/3/2023 Aeglea BioTherapeutics has 4.05 million AGLE shares outstanding. Investors often track the AGLE shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows AGLE share count trends over time, with 33 historical shares outstanding datapoints presented, dating back to 4/7/2016.
| AGLE Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AGLE Historical Shares Outstanding: +33.35% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| AGLE Stock Price Chart |
| About Spyre Therapeutics Inc |
| Aeglea BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biotechnology company developing human enzyme therapeutics for people with rare metabolic diseases. Co.'s development programs include: Pegzilarginase in Arginase 1 Deficiency, which is a recombinant human Arginase 1 that enzymatically degrades the amino acid arginine and improves the stability and arginine-degrading activity of the enzyme in human plasma; and AGLE-177 in Homocystinuria, which is a PEGylated, or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine. Co.'s preclinical pipeline includes cystinuria program to reduce plasma cystine and cysteine levels. We show 33 historical shares outstanding datapoints in our coverage of AGLE's shares outstanding history. Understanding the changing numbers of AGLE shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like AGLE versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching AGLE by allowing them to research AGLE shares outstanding history as well as any other stock in our coverage universe. |
| AGLE Current Stock Quote |
Quotes delayed 20 minutes  Free AGLE Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| AGLE Share Performance |
| Shares Outstanding Peers |
| Aeglea BioTherapeutics (AGLE) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
AGN Shares Outstanding History AGPU Shares Outstanding History AGRX Shares Outstanding History AGTC Shares Outstanding History AGTI Shares Outstanding History AHCO Shares Outstanding History AHPI Shares Outstanding History AIFC Shares Outstanding History AIKI Shares Outstanding History AIMD Shares Outstanding History More Healthcare companies » |
AGLE Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
